Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cyrano Therapeutics Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific matter is assigned to examiner MEYERS, ELIZABETH ANNE, who represents the distinct examiner currently reviewing the company's active applications. The concentration of work in a distinct art unit indicates a focused prosecution strategy at this stage of portfolio development.
With MEYERS, ELIZABETH ANNE handling the busiest examiner pending count of 1, the company faces a consolidated point of contact for its active intellectual property interests. This focus means that the outcome of the current prosecution depends on the interpretation of an individual within a specific technical department. For a practitioner, this environment suggests that building a consistent rapport with the assigned examiner is a primary factor in navigating the USPTO. The absence of multiple distinct examiners or art units reduces the complexity of tracking various examiner preferences. Consequently, the company's immediate patent strategy is tied to the progress of this individual application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEYERS, ELIZABETH ANNE | 1 | 22.2% | +93.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18760128 | Improved Nasal Administration of Parkinson's Therapeutics | MEYERS, ELIZABETH ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18760128 | Improved Nasal Administration of Parkinson's Therapeutics | MEYERS, ELIZABETH ANNE | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18760128 | Improved Nasal Administration of Parkinson's Therapeutics | MEYERS, ELIZABETH ANNE | 1617 | §103§112 | Non-Final OA | — | Pending | Jul 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCyrano Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Elizabeth Anne Meyers has the most, with 1 of Cyrano Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
